DK3415517T3 - Krystallinsk form af 1-(4-1-(2,6-difluorbenzyl)-5-dimethylaminomethyl-3-(6- methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin- 6yl)phenyl)-3-methoxyurea - Google Patents

Krystallinsk form af 1-(4-1-(2,6-difluorbenzyl)-5-dimethylaminomethyl-3-(6- methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin- 6yl)phenyl)-3-methoxyurea Download PDF

Info

Publication number: DK3415517T3
Authority: DK; Denmark
Prior art keywords: methoxyurea; methoxypyridazin; tetrahydrothieno; difluorobenzyl; dimethylaminomethyl
Prior art date: 2012-09-28

Application number

DK18185835.8T

Other languages

English (en)

Inventor

Kazuhiro Miwa

Tsuyoshi Sasaki

Fumiya Komura

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-28

Filing date

2013-09-27

Publication date

2022-05-30

2013-09-27 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2022-05-30 Application granted granted Critical

2022-05-30 Publication of DK3415517T3 publication Critical patent/DK3415517T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)

DK18185835.8T 2012-09-28 2013-09-27 Krystallinsk form af 1-(4-1-(2,6-difluorbenzyl)-5-dimethylaminomethyl-3-(6- methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin- 6yl)phenyl)-3-methoxyurea DK3415517T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2012217679		2012-09-28
EP13779938.3A EP2900675B1 (en)	2012-09-28	2013-09-27	Production method of thienopyrimidine derivative

Publications (1)

Publication Number	Publication Date
DK3415517T3 true DK3415517T3 (da)	2022-05-30

Family

ID=49448235

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK13779938.3T DK2900675T3 (da)	2012-09-28	2013-09-27	Fremgangsmåde til fremstilling af et thienopyrimidinderivat
DK18185835.8T DK3415517T3 (da)	2012-09-28	2013-09-27	Krystallinsk form af 1-(4-1-(2,6-difluorbenzyl)-5-dimethylaminomethyl-3-(6- methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin- 6yl)phenyl)-3-methoxyurea

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK13779938.3T DK2900675T3 (da)	2012-09-28	2013-09-27	Fremgangsmåde til fremstilling af et thienopyrimidinderivat

Country Status (20)

Country	Link
US (8)	US9758528B2 (da)
EP (3)	EP2900675B1 (da)
JP (1)	JP6250564B2 (da)
CN (3)	CN109053766B (da)
AR (1)	AR092707A1 (da)
CA (1)	CA2881132C (da)
CY (1)	CY1121641T1 (da)
DK (2)	DK2900675T3 (da)
ES (2)	ES2724206T3 (da)
HR (2)	HRP20220622T1 (da)
HU (2)	HUE059077T2 (da)
LT (2)	LT3415517T (da)
PL (2)	PL3415517T3 (da)
PT (2)	PT3415517T (da)
RS (2)	RS58703B1 (da)
SI (2)	SI2900675T1 (da)
TR (1)	TR201906318T4 (da)
TW (3)	TWI663171B (da)
UY (1)	UY35058A (da)
WO (1)	WO2014051164A2 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3415517T (lt)	2012-09-28	2022-06-10	Takeda Pharmaceutical Company Limited	Kristalinė 1-(4-(1-(2,6-difluorbenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)-2,4-diokso-1,2,3,4- tetrahidrotieno(2,3-d)pirimidin-6-il)fenil)-3-metoksikarbamido forma
PL3263110T3 (pl)	2015-02-26	2023-11-06	Takeda Pharmaceutical Company Limited	Tabletka zawierająca pochodną metoksymocznika i cząstki mannitolu
SI3518933T1 (sl)	2016-09-30	2022-06-30	Myovant Sciences Gmbh	Metode zdravljenja materničnih miom in endometrioze
CA3038875A1 (en)	2016-09-30	2018-04-05	Myovant Sciences Gmbh	Treatment of prostate cancer
HUE055891T2 (hu) *	2016-11-14	2022-01-28	Jiangsu Hengrui Medicine Co	A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja
AU2018280742B2 (en)	2017-06-05	2023-12-21	Kissei Pharmaceutical Co., Ltd.	Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
CN107188855A (zh) *	2017-07-14	2017-09-22	常州工程职业技术学院	一种3‑氨基‑6甲氧基哒嗪的制备方法
EP3765464A1 (en)	2018-03-14	2021-01-20	Teva Pharmaceuticals USA, Inc.	Solid state forms of relugolix
EP3666776A1 (en)	2018-12-11	2020-06-17	Sandoz AG	Hydrate of a gonadotropin-releasing hormone receptor antagonist
WO2020230094A1 (en) *	2019-05-15	2020-11-19	Dr. Reddy’S Laboratories Limited	Amorphous and crystalline forms of relugolix
CN110194776B (zh) *	2019-06-27	2021-05-28	四川伊诺达博医药科技有限公司	一种瑞卢戈利的合成方法
CN111943960B (zh) *	2019-07-29	2022-02-15	广东东阳光药业有限公司	取代的嘧啶二酮类化合物及其用途
JP2022542159A (ja) *	2019-08-02	2022-09-29	ジョンソン、マッセイ、パブリック、リミテッド、カンパニー	固体形態レルゴリクス（Ｒｅｌｕｇｏｌｉｘ）
CN112321602A (zh) *	2019-08-05	2021-02-05	苏州鹏旭医药科技有限公司	一种瑞卢戈利药物中间体的制备方法
CN112390812A (zh) *	2019-08-14	2021-02-23	苏州鹏旭医药科技有限公司	瑞卢戈利化合物的晶型和无定型固体及其制备方法
CN112771052B (zh) *	2019-08-21	2023-04-07	深圳仁泰医药科技有限公司	促性腺素释放激素拮抗剂的晶型及其制备方法和用途
CN115279769A (zh) *	2019-10-10	2022-11-01	梦欧文科学有限责任公司	N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
EP4041738A1 (en) *	2019-10-10	2022-08-17	Myovant Sciences GmbH	Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN112745304A (zh) *	2019-10-29	2021-05-04	上海度德医药科技有限公司	一种Relugolix的制备方法及中间体化合物
CN111423452B (zh) *	2020-03-26	2023-08-22	江西青峰药业有限公司	瑞卢戈利的中间体及其制备方法和应用
CN113444105A (zh) *	2020-03-27	2021-09-28	南京海润医药有限公司	一种Relugolix的制备方法
CN111333633B (zh) *	2020-04-01	2023-10-20	江西科睿药业有限公司	一种瑞卢戈利的中间体化合物及其制备方法和用途
CN111574534B (zh) *	2020-05-25	2021-06-04	东莞市东阳光新药研发有限公司	苯基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途
PE20230859A1 (es)	2020-05-29	2023-05-30	Myovant Sciences Gmbh	Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina
US11655256B1 (en)	2020-11-06	2023-05-23	Macfarlan Smith Limited	Processes for making a solid-state form of relugolix
JP2023549196A (ja)	2020-11-11	2023-11-22	ミオバントサイエンシズゲーエムベーハー	レルゴリクスの投与方法
CN112552312B (zh) *	2020-12-07	2022-08-05	杭州科巢生物科技有限公司	一种瑞卢戈利或其盐的合成方法
CN114685468A (zh) *	2020-12-25	2022-07-01	成都硕德药业有限公司	用于治疗子宫肌瘤的药物的中间体化合物及其制备方法
CN113620972A (zh) *	2021-02-02	2021-11-09	奥锐特药业(天津)有限公司	瑞卢戈利新晶型及其制备方法
CN114907370B (zh)	2021-02-10	2023-11-03	奥锐特药业(天津)有限公司	高纯度的噻吩并嘧啶化合物及其制备方法
CN115073491A (zh) *	2021-03-12	2022-09-20	上海医药工业研究院	一种瑞卢戈利中间体、其制备方法及其应用
WO2022214645A1 (en)	2021-04-09	2022-10-13	Farmhispania Group, S.L.	Processes and intermediates for the preparation of relugolix
CN115594688B (zh) *	2021-06-28	2023-11-17	成都倍特药业股份有限公司	瑞卢戈利中间体的制备方法
WO2023066941A1 (en) *	2021-10-18	2023-04-27	Myovant Sciences Gmbh	Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN114230576A (zh) *	2021-12-21	2022-03-25	伊诺药物研究(南京)有限公司	一种瑞卢戈利的制备方法
WO2023119333A1 (en) *	2021-12-25	2023-06-29	Dr. Reddy’S Laboratories Limited	Process for preparation of relugolix and its intermediates
CN114409629B (zh) *	2022-02-22	2023-12-29	浙江科聚生物医药有限公司	一种高纯度Relugolix关键中间体的制备方法及应用
CN114790189B (zh) *	2022-02-24	2023-06-09	海化生命(厦门)科技有限公司	瑞卢戈利中间体的制备方法
CN114755320B (zh) *	2022-03-17	2024-10-01	南京方生和医药科技有限公司	一种3-氨基-6-甲氧基哒嗪有关物质的检测方法
WO2023194924A1 (en) *	2022-04-08	2023-10-12	Glenmark Life Sciences Limited	Process for preparation of relugolix
CN114621249B (zh) *	2022-04-27	2024-01-26	江苏慧聚药业股份有限公司	瑞卢戈利关键中间体的制备
TW202345840A (zh) *	2022-05-05	2023-12-01	台灣神隆股份有限公司	瑞格列克及其中間體的製備方法
CN117285506A (zh) *	2022-07-14	2023-12-26	江西同和药业股份有限公司	一种瑞卢戈利中间体及其制备方法
CN115594689B (zh) *	2022-07-14	2024-03-19	江西同和药业股份有限公司	一种瑞卢戈利中间体、一种瑞卢戈利的合成方法
CN115417883B (zh) *	2022-09-16	2024-08-27	浙江科聚生物医药有限公司	一种瑞卢戈利的晶型及其制备方法
WO2024069492A1 (en)	2022-09-29	2024-04-04	Macfarlan Smith Limited	Processes for the preparation and manufacture of relugolix
CN115650950A (zh) *	2022-11-03	2023-01-31	江西同和药业股份有限公司	一种瑞卢戈利中间体及其制备方法以及一种酰胺缩合方法
WO2024126674A1 (en)	2022-12-15	2024-06-20	Medichem, S.A.	Process for the preparation of relugolix
CN115650965B (zh) *	2022-12-26	2023-03-31	南京威凯尔生物医药科技有限公司	一种瑞卢戈利关键中间体的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5116436B1 (da) *	1971-05-31	1976-05-24
EP0237289A3 (en) *	1986-03-14	1988-07-27	Takeda Chemical Industries, Ltd.	Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
JP2859791B2 (ja) *	1992-01-31	1999-02-24	吉富製薬株式会社	４−ブロモメチルビフェニル化合物の製造法
US5312958A (en)	1992-01-31	1994-05-17	Takeda Chemical Industries, Ltd.	Process for producing 4-bromomethylbiphenyl compounds
JPH10298156A (ja) *	1997-04-28	1998-11-10	Nippon Nohyaku Co Ltd	置換ハロメチルフェニルカルバミド酸エステル類の製造方法
TWI225863B (en) *	1999-03-24	2005-01-01	Takeda Chemical Industries Ltd	Thienopyrimidine compounds, their production and use
US6297379B1 (en)	1999-03-24	2001-10-02	Takeda Chemical Industries, Ltd.	Thienopyrimidine compounds, their production and use
KR20030005205A (ko)	2000-02-29	2003-01-17	다케다 야쿠힌 고교 가부시키가이샤	티에노피리미딘 유도체의 제조 방법
JP2001316391A (ja) *	2000-02-29	2001-11-13	Takeda Chem Ind Ltd	チエノピリミジン誘導体の製造法
GB2361917A (en) *	2000-05-04	2001-11-07	Astrazeneca Ab	Novel thieno[2,3-d]pyrimidinediones
JP2002068044A (ja)	2000-09-04	2002-03-08	Yamaha Motor Co Ltd	自動二輪車用ハンドルシート
JP2002088044A (ja) *	2000-09-14	2002-03-27	Sumitomo Seika Chem Co Ltd	４’−ブロモメチル−２−シアノビフェニルの製造方法
US7375109B2 (en)	2001-09-04	2008-05-20	N.V. Organon	Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity
WO2003064429A1 (fr) *	2002-01-30	2003-08-07	Takeda Chemical Industries, Ltd.	Thienopyrimidines, procedes de fabrication et d'utilisation correspondants
KR20050084311A (ko)	2002-12-20	2005-08-26	코닌클리즈케 필립스 일렉트로닉스 엔.브이.	비디오 이미지 개선 방법 및 이를 이용한 비디오 디코더,셋탑 박스, 텔레비전
ES2217956B1 (es) *	2003-01-23	2006-04-01	Almirall Prodesfarma, S.A.	Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
NZ541772A (en)	2003-01-29	2009-10-30	Takeda Pharmaceutical	Thienopyrimidine compounds and use thereof
WO2006014647A2 (en) *	2004-07-21	2006-02-09	Athersys, Inc.	Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
WO2006046485A1 (ja)	2004-10-25	2006-05-04	Nihon Nohyaku Co., Ltd.	畑作用除草剤組成物及び防除方法
ZA200801150B (en) *	2005-07-22	2010-05-26	Takeda Pharmaceutical	Premature ovulation preventive agent
WO2010026993A1 (ja)	2008-09-03	2010-03-11	武田薬品工業株式会社	製剤における吸収性改善方法および吸収性が改善された製剤
AP3649A (en) *	2011-02-23	2016-03-18	Lupin Ltd	Heteroaryl derivatives as alpha7 nachr modulators
JP2012217679A (ja)	2011-04-11	2012-11-12	Okumura Yu-Ki Co Ltd	パチンコ遊技機
LT3415517T (lt)	2012-09-28	2022-06-10	Takeda Pharmaceutical Company Limited	Kristalinė 1-(4-(1-(2,6-difluorbenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)-2,4-diokso-1,2,3,4- tetrahidrotieno(2,3-d)pirimidin-6-il)fenil)-3-metoksikarbamido forma
PL3263110T3 (pl)	2015-02-26	2023-11-06	Takeda Pharmaceutical Company Limited	Tabletka zawierająca pochodną metoksymocznika i cząstki mannitolu

2013
- 2013-09-27 LT LTEP18185835.8T patent/LT3415517T/lt unknown
- 2013-09-27 HR HRP20220622TT patent/HRP20220622T1/hr unknown
- 2013-09-27 PL PL18185835T patent/PL3415517T3/pl unknown
- 2013-09-27 SI SI201331414T patent/SI2900675T1/sl unknown
- 2013-09-27 EP EP13779938.3A patent/EP2900675B1/en active Active
- 2013-09-27 DK DK13779938.3T patent/DK2900675T3/da active
- 2013-09-27 TW TW107136006A patent/TWI663171B/zh active
- 2013-09-27 TW TW102134983A patent/TWI602819B/zh active
- 2013-09-27 UY UY0001035058A patent/UY35058A/es not_active Application Discontinuation
- 2013-09-27 AR ARP130103480A patent/AR092707A1/es unknown
- 2013-09-27 LT LTEP13779938.3T patent/LT2900675T/lt unknown
- 2013-09-27 WO PCT/JP2013/077013 patent/WO2014051164A2/en active Application Filing
- 2013-09-27 RS RS20190473A patent/RS58703B1/sr unknown
- 2013-09-27 CN CN201811130716.8A patent/CN109053766B/zh active Active
- 2013-09-27 JP JP2014557263A patent/JP6250564B2/ja active Active
- 2013-09-27 US US14/432,188 patent/US9758528B2/en active Active
- 2013-09-27 PT PT181858358T patent/PT3415517T/pt unknown
- 2013-09-27 EP EP18185835.8A patent/EP3415517B1/en active Active
- 2013-09-27 CA CA2881132A patent/CA2881132C/en not_active Expired - Fee Related
- 2013-09-27 HU HUE18185835A patent/HUE059077T2/hu unknown
- 2013-09-27 PT PT13779938T patent/PT2900675T/pt unknown
- 2013-09-27 CN CN201380051107.2A patent/CN104703992B/zh active Active
- 2013-09-27 RS RS20220449A patent/RS63199B1/sr unknown
- 2013-09-27 EP EP22168256.0A patent/EP4119564A1/en active Pending
- 2013-09-27 SI SI201331988T patent/SI3415517T1/sl unknown
- 2013-09-27 TW TW106130632A patent/TWI641611B/zh active
- 2013-09-27 DK DK18185835.8T patent/DK3415517T3/da active
- 2013-09-27 ES ES13779938T patent/ES2724206T3/es active Active
- 2013-09-27 HU HUE13779938A patent/HUE044048T2/hu unknown
- 2013-09-27 ES ES18185835T patent/ES2913753T3/es active Active
- 2013-09-27 CN CN202110609164.4A patent/CN113372358B/zh active Active
- 2013-09-27 PL PL13779938T patent/PL2900675T3/pl unknown
- 2013-09-27 TR TR2019/06318T patent/TR201906318T4/tr unknown
2017
- 2017-04-07 US US15/481,505 patent/US10150778B2/en active Active
2018
- 2018-07-12 US US16/034,002 patent/US10464945B2/en active Active
- 2018-08-29 US US16/116,804 patent/US10544160B2/en active Active
2019
- 2019-04-17 HR HRP20190729TT patent/HRP20190729T1/hr unknown
- 2019-05-21 CY CY20191100544T patent/CY1121641T1/el unknown
- 2019-12-11 US US16/710,390 patent/US11053257B2/en active Active
2021
- 2021-06-16 US US17/349,584 patent/US11731983B2/en active Active
2022
- 2022-03-14 US US17/694,635 patent/US11795178B2/en active Active
2023
- 2023-03-15 US US18/121,886 patent/US20230212184A1/en active Pending

Also Published As

Publication number	Publication date
JP6250564B2 (ja)	2017-12-20
JP2015532262A (ja)	2015-11-09
RS58703B1 (sr)	2019-06-28
CN113372358A (zh)	2021-09-10
SI3415517T1 (sl)	2022-06-30
US20150266891A1 (en)	2015-09-24
HRP20190729T1 (hr)	2019-06-14
LT2900675T (lt)	2019-05-27
EP4119564A1 (en)	2023-01-18
CN104703992A (zh)	2015-06-10
CA2881132A1 (en)	2014-04-03
SI2900675T1 (sl)	2019-06-28
US10150778B2 (en)	2018-12-11
AR092707A1 (es)	2015-04-29
US11053257B2 (en)	2021-07-06
PL3415517T3 (pl)	2022-07-04
PL2900675T3 (pl)	2019-08-30
US20220135585A1 (en)	2022-05-05
US9758528B2 (en)	2017-09-12
US11795178B2 (en)	2023-10-24
CN104703992B (zh)	2019-03-05
PT3415517T (pt)	2022-05-13
TWI663171B (zh)	2019-06-21
CN109053766B (zh)	2021-06-22
TW201418262A (zh)	2014-05-16
DK2900675T3 (da)	2019-06-03
ES2724206T3 (es)	2019-09-09
US10544160B2 (en)	2020-01-28
US20170210753A1 (en)	2017-07-27
TWI641611B (zh)	2018-11-21
UY35058A (es)	2014-04-30
LT3415517T (lt)	2022-06-10
US20190055261A1 (en)	2019-02-21
TW201808962A (zh)	2018-03-16
TW201906847A (zh)	2019-02-16
WO2014051164A2 (en)	2014-04-03
US11731983B2 (en)	2023-08-22
PT2900675T (pt)	2019-05-28
EP3415517A1 (en)	2018-12-19
US20180319816A1 (en)	2018-11-08
WO2014051164A3 (en)	2014-05-22
US10464945B2 (en)	2019-11-05
EP3415517B1 (en)	2022-04-20
RS63199B1 (sr)	2022-06-30
US20230212184A1 (en)	2023-07-06
EP2900675B1 (en)	2019-03-06
US20220204525A1 (en)	2022-06-30
CN109053766A (zh)	2018-12-21
TR201906318T4 (tr)	2019-05-21
US20200361953A1 (en)	2020-11-19
HUE044048T2 (hu)	2019-09-30
ES2913753T3 (es)	2022-06-06
HRP20220622T1 (hr)	2022-06-24
CY1121641T1 (el)	2020-07-31
TWI602819B (zh)	2017-10-21
HUE059077T2 (hu)	2022-11-28
CA2881132C (en)	2020-11-24
CN113372358B (zh)	2024-05-14
EP2900675A2 (en)	2015-08-05

Publication	Publication Date	Title
DK3415517T3 (da)	2022-05-30	Krystallinsk form af 1-(4-1-(2,6-difluorbenzyl)-5-dimethylaminomethyl-3-(6- methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin- 6yl)phenyl)-3-methoxyurea
SMT201700094B (it)	2017-03-08	Composto di pirazina carbossammide
DK3725778T3 (da)	2021-09-20	Formuleringer af enzalutamid
DK3431921T3 (da)	2020-05-04	System med integration af 3d-brugerinterface
DK2892550T3 (da)	2020-03-30	Stabile vandige formuleringer af adalimumab
DK2774302T3 (da)	2019-11-18	Passivt optisk netværk med asymmetrisk modulationsskema
CO6811863A2 (es)	2013-12-16	Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
DK2831510T3 (da)	2019-10-07	Varmepumpesystem, der anvender latent varme
DK3595281T3 (da)	2022-05-16	Skalerbare systemer til styring af farvehåndtering omfattende forskellige niveauer af metadata
DK3336097T3 (da)	2020-09-28	Fremstilling af ikke-krystallinsk obeticholsyre
DK2619664T3 (da)	2022-03-07	Validering af tolerancen af applikationer i netværk
DK2822568T3 (da)	2020-08-10	Anvendelser af caseinsammensætninger
DK3461895T3 (da)	2020-07-20	Modulation af ube3a-ats-ekspression
EP2884982A4 (en)	2016-03-30	SUBSTITUTED RATE (SYK) PHENYL TYROSINE KINASE INHIBITORS
DK2797581T3 (da)	2020-07-20	Formuleringer af (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methansulfonylethyl]-4-acetylaminoisoindolin-1,3-dion
DK3106150T3 (da)	2021-11-01	Forbedrede farmaceutiske sammensætninger af pimobendan
DK2867230T3 (da)	2020-04-14	Fremgangsmåde til fremstilling af 3,5-disubstitueret 1,2,4-oxadiazoler
DK2891494T3 (da)	2023-10-23	Fremgangsmåde til administration af hypnotisserende/beroligende midler
DK2833884T3 (da)	2020-08-10	Anvendelse af ccr3-inhibitorer
DK2832740T3 (da)	2019-07-15	SALT AF 1-(2-DEOXY-2-FLUOR-4-THIO-beta-D-ARABINOFURANOSYL)CYTOSIN
HK1214017A1 (zh)	2016-07-15	信息技術服務的管理
DK2931313T3 (da)	2019-07-15	Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer
DK2919777T3 (da)	2020-03-09	Transmukosal afgivelse af tocotrienol
CL2014002034A1 (es)	2014-11-14	Compuestos derivados de isoxazol-fenil-azetidina fenil sustituidos; y compuestos intermediarios.
DK2753306T3 (da)	2020-12-14	Faste doseringsformer af (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chlor-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat